Brief: Shanghai Henlius Biotech Announces License Agreement With Eisai
05/02/2026 10:16
Feb 5 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: LICENSE AGREEMENT WITH EISAI IN RESPECT OF HANSIZHUANG GRANTED EISAI CO LICENSE TO DEVELOP, MANUFACTURE & COMMERCIALISE HANSIZHUANG EISAI TO PAY HENLIUS $75 MILLION UPFRONT FEE, UPON EXECUTION OF LICENSE AGREEMENT EISAI TO PAY UP TO $233.33 MILLION IN COMMERCIAL SALES MILESTONES, OTHERS Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln